EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adjuvant treatment preferences in high-risk upper tract urothelial carcinoma: the perspective of Portuguese medical oncologists

Guilherme Vilhais iD, Mário Fontes-Sousa

The Oncologist · 2025

DOI: 10.1093/oncolo/oyaf365 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2025. Verfasst von Guilherme Vilhais und 1 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology Department, CUF Oncology, Lisbon 1350-352, Portugal. Hauptthemen laut MEDLINE: Oncologists, Carcinoma, Transitional Cell, Urologic Neoplasms. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CUF Academic Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although upper tract urothelial carcinoma (UTUC) and bladder urothelial carcinoma (BUC) share histological features, they differ in clinical behavior and management. Valid adjuvant options include surveillance, platinum-based chemotherapy, and immune checkpoint inhibitors (ICIs). To assess real-world practice, we conducted a survey among Portuguese medical oncologists dedicated to genitourinary malignancies, exploring their preferences for adjuvant therapy in high-risk UTUC (illustrated as pT2N1M0) across three clinical scenarios that differed by PD-L1 status and renal function. Among 34 respondents, cisplatin plus gemcitabine was the preferred regimen in cisplatin-eligible patients, regardless of PD-L1 status (94% in PD-L1-negative and 85% in PD-L1-positive tumors). In PD-L1-positive, cisplatin-ineligible patients, carboplatin plus gemcitabine was preferred (47%), followed by ICIs (44%). These findings suggest a consistent preference for platinum-based chemotherapy, likely reflecting UTUC-specific evidence from the POUT trial and apparent limited ICI benefit in this subgroup, underscoring the need for dedicated prospective trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OncologistsCarcinoma, Transitional CellUrologic NeoplasmsHumansPortugalChemotherapy, AdjuvantMaleFemaleMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsGemcitabineCisplatinDeoxycytidine

Stichwörter der Autor:innen

immune checkpoint inhibitorsplatinum-based chemotherapyupper tract urothelial carcinoma

Substanzen

GemcitabineCisplatinDeoxycytidine

Autor:innen und Institutionen

  • Hematology and Oncology Department, CUF Oncology, Lisbon 1350-352, Portugal.
  • Medical Oncology Department, ULS Lisboa Ocidental, Lisbon 1449-005, Portugal.

ORCID-Profile: Guilherme Vilhais

Förderung

  • CUF Academic Center

Zitieren

APA

Vilhais, G., & Fontes-Sousa, M. (2025). Adjuvant treatment preferences in high-risk upper tract urothelial carcinoma: the perspective of Portuguese medical oncologists. The Oncologist. https://doi.org/10.1093/oncolo/oyaf365

Vancouver

Vilhais G, Fontes-Sousa M. Adjuvant treatment preferences in high-risk upper tract urothelial carcinoma: the perspective of Portuguese medical oncologists. The Oncologist. 2025. doi:10.1093/oncolo/oyaf365

BibTeX
@article{Vilhais2025,
  author = {Vilhais, Guilherme and Fontes-Sousa, Mário},
  title = {Adjuvant treatment preferences in high-risk upper tract urothelial carcinoma: the perspective of Portuguese medical oncologists},
  journal = {The Oncologist},
  year = {2025},
  doi = {10.1093/oncolo/oyaf365}
}
Kostenlos starten →